Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 through 65 years~* Has a diagnosis of ankylosing spondylitis (AS) based on the Modified New York Criteria~* Has active AS, as defined by fulfillment of at least 2 of the following 3 conditions at both Screening and Baseline visits:~  * BASDAI score at least 4 cm~ * Total back pain on a visual analog scale (VAS) at least 40 mm~ * Morning stiffness at least 1 hr~* Has inadequate response to or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs) as defined by the Investigator~Exclusion Criteria:~* Has total spinal ankylosis (bamboo spine)~* Has undergone spinal surgery or joint surgery involving joints assessed within 2 months prior to Baseline~* Has extra-articular manifestations (i.e., psoriasis, uveitis, inflammatory bowel disease) that is not clinically stable, as defined by the Investigator's best clinical judgment, for at least 28 days prior to Baseline~* Has received intra-articular joint injection(s), spinal or paraspinal injection(s) with corticosteroids within 28 days prior to Baseline~* Has prior exposure to any biologic therapy with potential therapeutic impact on AS, including anti-TNF (tumor necrosis factor) therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
- Adalimumab (Type: EXPERIMENTAL): Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).